NASDAQ:NVUS - Novus Therapeutics Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $6.51 0.00 (0.00 %) (As of 07/22/2018 03:53 PM ET)Previous Close$6.51Today's Range$6.5034 - $6.984352-Week Range$3.12 - $8.61Volume3,938 shsAverage Volume19,407 shsMarket Capitalization$61.24 millionP/E RatioN/ADividend YieldN/ABeta0.55 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Novus Therapeutics, Inc., a pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is (OP-02), a surfactant-based combination drug product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology (OP-01) that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California. Receive NVUS News and Ratings via Email Sign-up to receive the latest news and ratings for NVUS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:NVUS CUSIPN/A Webwww.novustherapeutics.com Phone949-238-8090 Debt Debt-to-Equity RatioN/A Current Ratio14.92 Quick Ratio14.92 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book Value$2.75 per share Price / Book2.37 Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-13,110,000.00 Net MarginsN/A Return on Equity-66.29% Return on Assets-60.21% Miscellaneous Employees7 Outstanding Shares9,410,000Market Cap$61.24 Novus Therapeutics (NASDAQ:NVUS) Frequently Asked Questions What is Novus Therapeutics' stock symbol? Novus Therapeutics trades on the NASDAQ under the ticker symbol "NVUS." How were Novus Therapeutics' earnings last quarter? Novus Therapeutics Inc (NASDAQ:NVUS) posted its earnings results on Friday, May, 11th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.29) by $0.07. View Novus Therapeutics' Earnings History. What price target have analysts set for NVUS? 1 analysts have issued 1-year target prices for Novus Therapeutics' stock. Their predictions range from $7.00 to $7.00. On average, they expect Novus Therapeutics' stock price to reach $7.00 in the next year. This suggests a possible upside of 7.5% from the stock's current price. View Analyst Ratings for Novus Therapeutics. What is the consensus analysts' recommendation for Novus Therapeutics? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novus Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." Who are some of Novus Therapeutics' key competitors? Some companies that are related to Novus Therapeutics include resTORbio (TORC), DURECT (DRRX), Galmed Pharmaceuticals (GLMD), Strongbridge Biopharma (SBBP), Kamada (KMDA), Ocular Therapeutix (OCUL), Cue Biopharma (CUE), Teligent (TLGT), Sierra Oncology (SRRA), MannKind (MNKD), Neptune Technologies & Bioressources (NEPT), ProQR Therapeutics (PRQR), Chimerix (CMRX), Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (ZOM) and REDHILL BIOPHAR/S (RDHL). Who are Novus Therapeutics' key executives? Novus Therapeutics' management team includes the folowing people: Mr. Gregory J. Flesher, CEO & Director (Age 48)Dr. Catherine C. Turkel PharmD, MBA, Ph.D., Pres (Age 57)Mr. Jon Kuwahara CPA, Sr. VP of Fin. & Admin. (Age 53)Ms. Christine G. Ocampo CPA, Consultant (Age 46) Has Novus Therapeutics been receiving favorable news coverage? Media stories about NVUS stock have been trending somewhat positive on Sunday, Accern reports. The research firm identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Novus Therapeutics earned a news impact score of 0.09 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 45.92 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term. How do I buy shares of Novus Therapeutics? Shares of NVUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Novus Therapeutics' stock price today? One share of NVUS stock can currently be purchased for approximately $6.51. How big of a company is Novus Therapeutics? Novus Therapeutics has a market capitalization of $61.24 million. Novus Therapeutics employs 7 workers across the globe. How can I contact Novus Therapeutics? Novus Therapeutics' mailing address is 19900 MACARTHUR BLVD. SUITE 550, IRVINE CA, 92612. The biopharmaceutical company can be reached via phone at 949-238-8090 or via email at [email protected] MarketBeat Community Rating for Novus Therapeutics (NASDAQ NVUS)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 132 (Vote Outperform)Underperform Votes: 134 (Vote Underperform)Total Votes: 266MarketBeat's community ratings are surveys of what our community members think about Novus Therapeutics and other stocks. Vote "Outperform" if you believe NVUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVUS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/22/2018 by MarketBeat.com StaffFeatured Article: Are Wall Street analysts' stock ratings worth following?